BURNABY, BC, Sept. 7 /CNW/ - Welichem Biotech Inc. (“WBI” or the “Company”) (TSX-V: WBI - News) is very pleased to report that the Phase I Clinical Trials of the Company’s anti-psoriasis drug candidate, WBI-1001, are running as planned in Montreal, Quebec. The trials consist of six separate cohorts. All six patients in Cohort I have been treated with WBI-1001 for at least fourteen days and none has experienced any adverse side effects. Patients for Cohor
